Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV000129952 | SCV000184775 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2014-02-24 | criteria provided, single submitter | clinical testing | ​The p.E330G variant (also known as c.989A>G) is located in coding exon 8 of the SMAD4 gene. This alteration results from a A to G substitution at nucleotide position 989. The glutamic acid at codon 330 is replaced by glycine, an amino acid with similar properties. This mutation has been reported in multiple individuals diagnosed with juvenile polyposis syndrome (JPS) (Sayed, MG et al. Ann Surg Oncol. 2002 Nov;9(9):901-6; van Hattem, WA et al. Gut. 2008 May;57(5):623-7). In addition, an alteration at the same codon, p.E330K, was reported in a patient diagnosed with both JPS and hereditary hemorrhagic telangiectasia (HHT), whom had a family history of both conditions (Gallione, C et al. Am J Med Genet A. 2010 Feb;152A(2):333-9). This variant was not reported in population-based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP) and 1000 Genomes Project. To date, this alteration has been detected with an allele frequency of approximately 0.01% (greater than 7,000 alleles tested) in our clinical cohort (includes this individual). Based on protein sequence alignment, this amino acid position is completely conserved in available vertebrate species. In addition, this alteration is predicted to be probably damaging and deleterious by PolyPhen and SIFT in silico analyses, respectively. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
| Uni |
RCV000059737 | SCV000091307 | not provided | not provided | no assertion provided | not provided |